Previous 10 | Next 10 |
Data for OTO-413 in hearing loss is due early in Q2 2002. Data for OTO-313 in tinnitus is due mid-2022. Tinnitus and hearing loss are indications with no FDA-approved medicines and are each billion-dollar markets. Precedent suggests developing therapeutics for these indication...
Frequency Therapeutics press release (NASDAQ:FREQ): Q4 GAAP EPS of -$0.62 misses by $0.98. “The year ahead has numerous milestones for Frequency and our lead program FX-322, as we plan to complete enrollment and work toward a readout of our FX-322-208 Phase 2b study of individuals with...
Company Reports Steady Enrollment for FX-322-208 Phase 2b Study in Individuals with Sudden and Noise-Induced Sensorineural Hearing Loss; Topline Results Anticipated in Q4 2022 or Q1 2023 Continued Progress on Second Program for Hearing Restoration, FX-345; Phase 1b Start Antic...
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will participate...
Company to Review Milestones for its Phase 2b Study of FX-322, the Near-Term Clinical Plan for its Second Hearing Restoration Asset, FX-345, and Selection of a Lead Candidate for its Novel Multiple Sclerosis Program that Has Shown Potent Pre-Clinical Data Frequency Therapeut...
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today shared the results from its FX-322-113 study, a placebo-controlled trial ...
Gainers: Stitch Fix (NASDAQ:SFIX) +2%. Fate Therapeutics (NASDAQ:FATE) +2%. Frequency Therapeutics (NASDAQ:FREQ) +1%. Criteo (NASDAQ:CRTO) +1%. EVgo (NASDAQ:EVGO) +1%. Losers: Nexters (NASDAQ:GDEV) -3%. Ocular Therapeutix (NASDAQ:OCUL) -2%. Sig...
Frequency Therapeutics (NASDAQ:FREQ): Q3 GAAP EPS of -$0.73. Cash and cash equivalents of $160.5M Press Release For further details see: Frequency Therapeutics reports Q3 results
Enrollment Underway for FX-322-208 Phase 2b Study in Subjects with Sudden and Noise-Induced Sensorineural Hearing Loss; Aligns with FDA on Speech Perception as Primary Endpoint for FX-322 Studies Expands Pipeline with New Pre-Clinical Program for Hearing Restoration that May P...
Management and Leading KOLs will Provide Detailed Review of Completed FX-322 Clinical Data in Subjects with Sensorineural Hearing Loss (SNHL), Supporting Design of FX-322-208 Phase 2b Study New Hearing Restoration Program Advances Toward Clinical Studies Providing Broader Coch...
News, Short Squeeze, Breakout and More Instantly...
Frequency Therapeutics Inc. Company Name:
FREQ Stock Symbol:
NYSE Market:
Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. In July, the Company announced that it entered into a definitive merger agreement with Korro Bio, Inc., a leading RNA editing company focused on the d...
2023-07-15 06:36:00 ET 3 Things to Know About Using Analyst Opinions for Trading Penny Stocks Trading penny stocks can be a thrilling venture, offering the potential for significant returns on small investments. One of the key aspects that can influence the success of such trades is the...
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase ...